EAM Investors’s Collegium Pharmaceutical COLL Stock Holding History

EAM Investors’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-79,949	Closed	-$3.1M	–	270
2024 Q1	$3.1M	Buy	+79,949	New	+$2.8M	0.48%	116
2023 Q2	–	Sell	-80,989	Closed	-$1.94M	–	286
2023 Q1	$1.94M	Buy	+80,989	New	+$2.15M	0.38%	115
2020 Q2	–	Sell	-101,067	Closed	-$1.65M	–	268
2020 Q1	$1.65M	Buy	101,067 +13,227	+15%	+$273K	0.51%	85
2019 Q4	$1.81M	Buy	+87,840	New	+$1.46M	0.4%	95
2018 Q2	–	Sell	-148,629	Closed	-$3.8M	–	300
2018 Q1	$3.8M	Buy	+148,629	New	+$3.54M	0.63%	31
2016 Q2	–	Sell	-127,021	Closed	-$2.31M	–	311
2016 Q1	$2.31M	Buy	127,021 +84,171	+196%	+$1.53M	0.36%	140
2015 Q4	$1.18M	Sell	42,850 -966	-2%	-$20.4K	0.15%	242
2015 Q3	$969K	Buy	+43,816	New	+$792K	0.15%	265

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

EAM Investors's COLL Position: Q2 2024 in Review

EAM Investors sold out of Collegium Pharmaceutical (COLL) in Q2 2024, closing a stake of 79,949 shares — an estimated $3.1M sold.

EAM Investors first reported a position in COLL in Q3 2015 and held it in 8 quarters. The position peaked at $3.8M in Q1 2018. 229 funds tracked by Wall St. Rank hold COLL as of Q2 2024.

EAM Investors reported no remaining Collegium Pharmaceutical position as of Q2 2024 after selling out during the quarter.
EAM Investors sold 79,949 Collegium Pharmaceutical shares in Q2 2024, an estimated $3.1M.
EAM Investors first reported a position in Collegium Pharmaceutical in Q3 2015 and held it in 8 quarters.
EAM Investors's Collegium Pharmaceutical position peaked at $3.8M in Q1 2018.
229 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.